Latest: FDA Approves New Biosimilar for Oncology Treatment
Healthcare Business

Roflumilast Cream 0.05% Durable, Safe for Younger Pediatric Patients

by American Journal Managed Care
0 Comments
0 Mins
The INTEGUMENT-OLE study is an open-label extension analysis that followed a primary investigation from the phase 3 INTEGUMENT-PED trial, which investigated the efficacy and safety of once-daily roflumilast cream 0.05% for atopic dermatitis in children aged 2 to 5 years.
Tags:
American Journal Managed Care
Author

American Journal Managed Care

Previous Post
KFF/ESPN Survey of 1988 NFL Players Finds the Vast Majority Say Pro Football Left Them With a Range of Serious Health Problems, but Most Would Play Again and Encourage Their Kids To Play
Next Post
GLP-1s’ Preoperative Use Requires Safety Considerations
📢

Advertisement

300x250 Banner

Recent Content

COPD Biologics: Early Treatment Insights

Pulmonology • 2 hours ago

Antihypertensive Medication Guidelines

Cardiology • 4 hours ago

Juvenile Arthritis Care Transition

Rheumatology • 6 hours ago